Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.
Sarepta CEO Ed Kaye said he's stepping down.
Apple isn't the biggest winner from Trump's plans for a tax holiday. These three stocks are...
The French drugs maker lead gainers in the Paris market after profits beat analyst consensus by about 13%.
Sales of cancer drug Opdivo were up 60% year-over-year, while sales of blood thinner Eliquis grew 50%.
Pacific Biosciences of California, Alexion Pharmaceuticals and Arena Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
Sales rose 4% and were 2% ahead of expectation on strong sales from core drugs and promising results from new treatments.
The drug company maintained its 2017 guidance, but sales of two of its key drugs registered disappointing results, and shares were down in after-hours trading 3%.